Do Your Eyes Always Feel Hard to Open? Are Your Upper Eyelids Becoming Increasingly “Heavy”?
As we age, some people may gradually develop drooping of the upper eyelids, also known as acquired ptosis. This can make the eyes appear tired or less alert, and in more severe cases, may even affect the upper field of vision.
Japan has recently introduced an eye drop for acquired ptosis: アップニークミニ点眼液0.1% (UPNEEQ Mini 0.1%).
UPNEEQ Mini 0.1% Eye Drops: A New Treatment Option for Acquired Ptosis
Do your eyes often feel difficult to open? Are your upper eyelids becoming increasingly “heavy”?
As we age, some people may gradually develop drooping of the upper eyelids, also known as acquired ptosis. This condition can make the eyes appear tired or less alert and, in more severe cases, may affect the upper field of vision.
Japan has introduced UPNEEQ Mini 0.1% Eye Drops (アップニークミニ点眼液0.1%), a prescription medication intended for the treatment of acquired ptosis.
Unlike ordinary eye-care drops, UPNEEQ Mini 0.1% is a medication specifically designed for acquired ptosis.
What Is Acquired Ptosis?
Simply put, acquired ptosis occurs when an upper eyelid that was previously normal gradually begins to droop due to factors such as aging or changes in the surrounding tissues.
Common symptoms may include:
Noticeable drooping of the upper eyelid
Reduced ability to open the eyes fully
A tired or “sleepy-looking” appearance
Possible obstruction of the upper visual field
Unconsciously raising the eyebrows or tilting the head back to see more clearly
Eye fatigue, especially after prolonged visual activity
If eyelid drooping becomes progressively more noticeable, it is recommended to consult an ophthalmologist to determine the underlying cause.
What Is UPNEEQ Mini 0.1%?
Product name: アップニークミニ点眼液0.1%
English name: UPNEEQ Mini 0.1% Eye Drops
The active ingredient is:
Oxymetazoline Hydrochloride
Strength and packaging:
0.1% | 0.3 mL × 30 single-use containers
This product is an ophthalmic medication used for acquired ptosis.
Its mechanism of action is related to the Müller’s muscle in the eyelid.
Oxymetazoline acts on adrenergic receptors in Müller’s muscle, causing the muscle to contract and helping to elevate the upper eyelid.
What Does UPNEEQ Mini 0.1% Help With?
The approved indication is:
Acquired ptosis
Its potential benefits can be understood as helping to:
Improve acquired ptosis
Help elevate the upper eyelid
Improve the degree to which the eyes can be opened
Help improve visual field limitations caused by eyelid drooping
Support elevation of the upper eyelid through its action on Müller’s muscle
It is important to note that this product is a medication, not an ordinary cosmetic or “beauty” eye drop.
It may not be suitable for every type or cause of ptosis.
How Is It Used?
According to the Japanese product instructions:
Adults: Instill 1 drop each time, once daily.
UPNEEQ Mini is supplied in single-use containers and is preservative-free.
Important precautions include:
Do not allow the tip of the container to touch the eye or other surfaces.
If using other eye drops, wait at least 5 minutes between products.
Discard any remaining solution after a single use.
Always use the medication according to the instructions of a doctor or pharmacist.
Important Safety Information
UPNEEQ Mini is a pharmaceutical product and should not be considered an ordinary eye-care product.
Possible adverse effects may include:
Mydriasis (pupil dilation)
Eyelid itching
Conjunctival hyperemia or redness
Blurred vision
Superficial punctate keratitis
Eyelid eczema
If pupil dilation or blurred vision occurs, avoid driving, cycling, or operating machinery until normal vision has returned.
People with certain conditions, including cardiovascular disease or angle-closure glaucoma, should consult a healthcare professional before using this medication.
People with a history of hypersensitivity or allergy to any of the product’s ingredients should not use it.
Product Information
Product Name: アップニークミニ点眼液0.1%
English Name: UPNEEQ Mini 0.1% Eye Drops
Active Ingredient: Oxymetazoline Hydrochloride
Strength: 0.1%
Package: 0.3 mL × 30 single-use containers
Indication: Acquired ptosis
Manufacturer: Santen Pharmaceutical Co., Ltd.
A New Treatment Option for Acquired Ptosis
Drooping eyelids are not simply a cosmetic concern. If your upper eyelids are gradually drooping, opening your eyes is becoming more difficult, or your vision is being affected, it is important to determine the underlying type and cause of the ptosis.
Rather than relying solely on ordinary eye-care or cosmetic products, seeking a professional ophthalmic evaluation may help identify the appropriate treatment approach.
UPNEEQ Mini 0.1% provides a medicated eye-drop treatment option for acquired ptosis.
However, it is important to remember that this is a pharmaceutical product. Whether it is appropriate for a particular individual should be determined by a qualified healthcare professional based on the person's specific condition.
#JapanMedicine #UPNEEQ #UPNEEQMini #Ptosis #AcquiredPtosis #Ophthalmology #SantenPharmaceutical #JapaneseEyeDrops #EyeHealth